Shionogi & Co., Ltd. Stock price

Equities

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange 01:00:00 2024-02-22 am EST 5-day change 1st Jan Change
7,147 JPY +1.26% Intraday chart for Shionogi & Co., Ltd. +2.17% +5.13%
Sales 2024 * 442B 2.94B Sales 2025 * 414B 2.75B Capitalization 2,020B 13.44B
Net income 2024 * 157B 1.04B Net income 2025 * 144B 962M EV / Sales 2024 * 3.51 x
Net cash position 2024 * 469B 3.12B Net cash position 2025 * 560B 3.73B EV / Sales 2025 * 3.53 x
P/E ratio 2024 *
13.1 x
P/E ratio 2025 *
14 x
Employees 5,680
Yield 2024 *
2.14%
Yield 2025 *
2.2%
Free-Float 90.1%
More Fundamentals * Assessed data
Dynamic Chart
ViiV Says Trial Data Shows Injectable HIV Treatment Cabenuva Has 'Superior Efficacy' Compared With Pills in Some People MT
ViiV's Long-acting Injectable HIV Drug Shown More Effective than Daily Pills in Phase 3 Study MT
Shionogi & Co., Ltd. Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open CI
Shionogi Buys Back Over 8 Billion Yen Worth of Shares in January MT
Shionogi's Nine-Month Profit, Revenue Slip on Lower Prescription Drug Sales MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023. CI
Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea MT
Shionogi & Co., Ltd Announces the Launch of Fetroja(Cefiderocol) Intravenous Infusion 1g Vial in Japan on December 20, 2023 CI
Shionogi Starts Late-Stage Additional-Dose Trial of Vaccine Against Omicron Subvariant MT
Shionogi & Co., Ltd. Initiation of a Phase 3 Additional Dose Clinical Trial in Japanese Subjects of the Monovalent Vaccine for the XBB1.5 Strain, S-268023 CI
Shionogi & Co Buys Back 1.23 Million Shares in November MT
StemRIM Enters into Contract for Implementation of Phase 2 Investigator-Initiated Clinical Trial Targeting Ischemic Cardiomyopathy Using Redasemtide, in Collaboration with Osaka University Hospital and Shionogi & Co CI
Japanese Shares Slip into Red After Downbeat Economic Data MT
Shionogi Bags Japan Health Regulator Approval for Intravenous Antibiotic MT
Shionogi &Co’s Attributable Profit up 98.4% in Fiscal H1 as Improved Revenue Further Boosted by Profit from License Transfer MT
More news
1 day+1.26%
1 week+2.17%
Current month+0.52%
1 month-3.73%
3 months+2.57%
6 months+12.82%
Current year+5.13%
More quotes
1 week
7 043.00
Extreme 7043
7 205.00
1 month
6 937.00
Extreme 6937
7 507.00
Current year
6 741.00
Extreme 6741
7 507.00
1 year
5 718.00
Extreme 5718
7 507.00
3 years
5 372.00
Extreme 5372
8 439.00
5 years
4 379.00
Extreme 4379
8 439.00
10 years
1 733.00
Extreme 1733
8 439.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 82-03-31
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 73 19-05-31
Chief Executive Officer 64 82-03-31
Director/Board Member 68 77-03-31
More insiders
Date Price Change Volume
24-02-22 7,147 +1.26% 1 573 700
24-02-21 7,058 -1.20% 1,020,100
24-02-20 7,144 +0.13% 774,800
24-02-19 7,135 -0.24% 795,600
24-02-16 7,152 +2.24% 1,301,900

Delayed Quote Japan Exchange, February 22, 2024 at 01:00 am EST

More quotes
Shionogi & Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. The group's activity is organized around 3 families of products: - prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.; - OTC products: analgesic products, vitamins and tonics, etc.; - diagnosis products: primarily for detection and treatment of cardiovascular diseases and immune system.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
7,058 JPY
Average target price
7,336 JPY
Spread / Average Target
+3.94%
Consensus
1st Jan change Capi.
+5.13% 13 445 M $
+27.96% 671 B $
+21.24% 538 B $
+1.24% 382 B $
+17.52% 325 B $
+13.02% 309 B $
-5.87% 211 B $
+6.37% 209 B $
-6.39% 198 B $
-3.89% 156 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Shionogi & Co., Ltd. - Japan Exchange
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer